ReviewDiagnostics (Basel, Switzerland)2015
Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review.
Review in Diagnostics (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed.
- Rare Gastroesophageal Tumor Subtypes: Clinicopathologic Characteristics, Molecular Alterations, and Therapeutic Implications.Cancers · 2026Review
- Histomorphological and Molecular Features of Colonic Large-Cell Neuroendocrine Carcinoma in a Patient With Familial Adenomatous Polyposis: A Case Report and Review of Literature.International journal of surgical pathology · 2026Review
- Unraveling the characteristics of early esophageal neuroendocrine carcinoma using multi-model endoscopy: A retrospective study of serial cases.World journal of gastrointestinal oncology · 2025Article
- Clinical application of targeted α-emitter therapy in gastroenteropancreatic neuroendocrine neoplasms.Journal of gastroenterology · 2025Review
- Gastroesophageal Neuroendocrine Tumors: Outcomes and Management.Journal of clinical medicine · 2025Review
- Insights into gastric mixed adenoneuroendocrine carcinoma: a novel comparative study of clinicopathological features and survival outcomes.Frontiers in endocrinology · 2025Article
- Neoadjuvant chemoimmunotherapy for small cell carcinoma of the esophagus: Clinical efficacy and biomarker exploration.Human vaccines & immunotherapeutics · 2024Article
- An unexpected case of large cell neuroendocrine carcinoma of the colon: a case report.Journal of gastrointestinal oncology · 2024Article
- Rare malignant neoplasm of the esophagus: current status and future perspectives.Japanese journal of clinical oncology · 2024Review
- High expression of insulinoma-associated protein 1 (INSM1) distinguishes colorectal mixed and pure neuroendocrine carcinomas from conventional adenocarcinomas with diffuse expression of synaptophysin.The journal of pathology. Clinical research · 2023Article
- Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcription.Science advances · 2023Article
- Role of Advanced Gastrointestinal Endoscopy in the Comprehensive Management of Neuroendocrine Neoplasms.Cancers · 2023Review
- Identification of a new prognostic score for patients with high-grade metastatic GEP-NEN treated with palliative chemotherapy.Journal of cancer research and clinical oncology · 2023Article
- Surgical Management of Pancreatic Neuroendocrine Tumors.Cancers · 2023Review
- Substance use and esophageal neuroendocrine neoplasm: A case-control study.The Kaohsiung journal of medical sciences · 2022Article
- Diagnosis and management of small bowel neuroendocrine tumors: A state-of-the-art.World journal of methodology · 2022Review
- Multifocal diffuse large cell neuroendocrine carcinoma of the colon.Journal of clinical and translational research · 2022Article
- Surgical Outcomes and Prognostic Factors of G3 Pancreatic Neuroendocrine Carcinomas: A Consecutive Analysis Based on Previous Study Results.Journal of clinical medicine · 2022Article
- Article
- New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.World journal of gastroenterology · 2022Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To date, empirical literature has generally been considered lacking in relation to neuroendocrine carcinomas (NECs), the highly malignant subgroup of neuroendocrine neoplasms. NECs are often found in the lungs or the gastroenteropancreatic (GEP) system and can be of small or large cell type. Concentrating on GEP-NECs, we can conclude that survival times are poor, with a median of only 4-16 months depending on disease stage and primary site. Further, this aggressive disease appears to be on the rise, with incidence numbers increasing while survival times are stagnant. Treatment strategies concerning surgery are often undecided and second-line chemotherapy is not yet established. After an analysis of over 2600 articles, we can conclude that there is indeed more empirical literature concerning GEP-NECs available than previously assumed. This unique review is based on 333 selected articles and contains detailed information concerning all aspects of GEP-NECs. Namely, the classification, histology, genetic abnormalities, epidemiology, origin, biochemistry, imaging, treatment and survival of GEP-NECs are described. Also, organ-specific summaries with more detail in relation to disease presentation, diagnosis, treatment and survival are presented. Finally, key points are discussed with directions for future research priorities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.